MX2018001351A - Inhibidores de los puntos de control inmunitarios para su uso en el tratamiento del cancer hematologico. - Google Patents
Inhibidores de los puntos de control inmunitarios para su uso en el tratamiento del cancer hematologico.Info
- Publication number
- MX2018001351A MX2018001351A MX2018001351A MX2018001351A MX2018001351A MX 2018001351 A MX2018001351 A MX 2018001351A MX 2018001351 A MX2018001351 A MX 2018001351A MX 2018001351 A MX2018001351 A MX 2018001351A MX 2018001351 A MX2018001351 A MX 2018001351A
- Authority
- MX
- Mexico
- Prior art keywords
- blood
- treatment
- immune
- checkpoint inhibitors
- pvrl2
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 title 1
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 title 1
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 title 1
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 title 1
- 102100035488 Nectin-2 Human genes 0.000 abstract 7
- 102100031351 Galectin-9 Human genes 0.000 abstract 3
- 101710121810 Galectin-9 Proteins 0.000 abstract 3
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 abstract 3
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 abstract 3
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 abstract 3
- 101150065403 NECTIN2 gene Proteins 0.000 abstract 3
- 108060005251 Nectin Proteins 0.000 abstract 3
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 abstract 3
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 abstract 3
- 239000003112 inhibitor Substances 0.000 abstract 3
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464499—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención proporciona un inhibidor de CD112 (Nectina-2, PVRL2), CD155 (PVR), Galectina-9, TIM-3 y/o TIGIT para su uso en un método de tratamiento del cáncer hematológico, en particular la leucemia mieloide aguda (AML). Además, la presente invención proporciona una composición farmacéutica que comprende un inhibidor de CD112 (Nectina-2, PVRL2), CD155 (PVR), Galectina-9, TIM-3 y/o TIGIT y una célula CAR-T. La presente invención además proporciona una composición farmacéutica que comprende un inhibidor de CD112 (Nectina-2, PVRL2), CD155 (PVR), Galectina-9, TIM-3 y/o TIGIT y un constructo de anticuerpo capaz de activar a los linfocitos T.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562201461P | 2015-08-05 | 2015-08-05 | |
PCT/EP2016/068726 WO2017021526A1 (en) | 2015-08-05 | 2016-08-05 | Immune-checkpoint inhibitors for use in the treatment of blood-borne cancers |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2018001351A true MX2018001351A (es) | 2018-05-22 |
Family
ID=56801503
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2018001351A MX2018001351A (es) | 2015-08-05 | 2016-08-05 | Inhibidores de los puntos de control inmunitarios para su uso en el tratamiento del cancer hematologico. |
Country Status (23)
Country | Link |
---|---|
US (2) | US20170037133A1 (es) |
EP (1) | EP3331915B1 (es) |
JP (1) | JP7170532B2 (es) |
CN (1) | CN108473572B (es) |
AU (1) | AU2016301961B2 (es) |
CA (1) | CA2996015A1 (es) |
DK (1) | DK3331915T3 (es) |
EA (1) | EA039307B1 (es) |
ES (1) | ES2861436T3 (es) |
HK (1) | HK1249524A1 (es) |
HU (1) | HUE053763T2 (es) |
IL (1) | IL256874B (es) |
JO (1) | JO3620B1 (es) |
LT (1) | LT3331915T (es) |
MX (1) | MX2018001351A (es) |
MY (1) | MY186582A (es) |
PH (1) | PH12018500120A1 (es) |
SG (1) | SG10202000914VA (es) |
SI (1) | SI3331915T1 (es) |
TW (1) | TWI719041B (es) |
UA (1) | UA125375C2 (es) |
WO (1) | WO2017021526A1 (es) |
ZA (1) | ZA201708598B (es) |
Families Citing this family (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10550173B2 (en) | 2015-02-19 | 2020-02-04 | Compugen, Ltd. | PVRIG polypeptides and methods of treatment |
DK3295951T3 (da) * | 2015-02-19 | 2020-07-20 | Compugen Ltd | Anti-pvrig-antistoffer og fremgangsmåder for anvendelse |
EP3288570A4 (en) | 2015-04-29 | 2018-11-21 | Fred Hutchinson Cancer Research Center | Modified stem cells and uses thereof |
TWI715587B (zh) | 2015-05-28 | 2021-01-11 | 美商安可美德藥物股份有限公司 | Tigit結合劑和彼之用途 |
US9861621B2 (en) * | 2015-06-29 | 2018-01-09 | Biomed Valley Discoveries, Inc. | LPT-723 and immune checkpoint inhibitor combinations and methods of treatment |
US11098130B1 (en) | 2015-08-03 | 2021-08-24 | Tasrif Pharmaceutical, LLC | Antibodies and antibody fragments against the CD155 receptor and methods of use thereof |
IL296874A (en) | 2016-03-01 | 2022-11-01 | Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd | Antibodies specific for the human poliovirus receptor |
CN109476751B (zh) | 2016-05-27 | 2024-04-19 | 艾吉纳斯公司 | 抗tim-3抗体及其使用方法 |
MY200602A (en) | 2016-07-14 | 2024-01-04 | Bristol Myers Squibb Co | Antibodies against tim3 and uses thereof |
MY194032A (en) | 2016-08-17 | 2022-11-09 | Compugen Ltd | Anti-tigit antibodies, anti-pvrig antibodies and combinations thereof |
EA201990591A1 (ru) | 2016-09-23 | 2019-08-30 | Фред Хатчинсон Кэнсер Рисерч Сентер | Tcr, специфичные к минорному антигену гистосовместимости (h) ha-1, и их применения |
CA3044664C (en) | 2016-11-30 | 2022-11-22 | Oncomed Pharmaceuticals, Inc. | Methods for treatment of cancer comprising tigit-binding agents |
SG11201908527SA (en) | 2017-03-15 | 2019-10-30 | Hutchinson Fred Cancer Res | High affinity mage-a1-specific tcrs and uses thereof |
DK3618863T3 (da) | 2017-05-01 | 2023-08-21 | Agenus Inc | Anti-tigit-antistoffer og fremgangsmåder til anvendelse deraf |
JOP20190260A1 (ar) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
JP7158416B2 (ja) | 2017-05-24 | 2022-10-21 | イーフェクター セラピューティクス, インコーポレイテッド | 抗腫瘍免疫応答を改善するための組成物および方法 |
US11225523B2 (en) | 2017-06-01 | 2022-01-18 | Compugen Ltd. | Triple combination antibody therapies |
WO2018229163A1 (en) * | 2017-06-14 | 2018-12-20 | King's College London | Methods of activating v delta 2 negative gamma delta t cells |
SG11202000660QA (en) | 2017-07-27 | 2020-02-27 | Iteos Therapeutics Sa | Anti-tigit antibodies |
KR20200041377A (ko) | 2017-09-06 | 2020-04-21 | 프레드 헛친슨 켄서 리서치 센터 | Strep-tag 특이적 결합 단백질 및 그 용도 |
JP7407701B2 (ja) | 2017-09-06 | 2024-01-04 | フレッド ハッチンソン キャンサー センター | strepタグ特異的キメラ受容体およびその使用 |
US20210106618A1 (en) | 2017-09-06 | 2021-04-15 | Fred Hutchinson Cancer Research Center | Methods for improving adoptive cell therapy |
EP3697435A1 (en) | 2017-10-20 | 2020-08-26 | Fred Hutchinson Cancer Research Center | Compositions and methods of immunotherapy targeting tigit and/or cd112r or comprising cd226 overexpression |
WO2019102456A1 (en) | 2017-11-27 | 2019-05-31 | University Of Rijeka Faculty Of Medicine | Immunotoxins for treating cancer |
WO2019109047A1 (en) | 2017-12-01 | 2019-06-06 | Fred Hutchinson Cancer Research Center | Binding proteins specific for 5t4 and uses thereof |
WO2019140278A1 (en) | 2018-01-11 | 2019-07-18 | Fred Hutchinson Cancer Research Center | Immunotherapy targeting core binding factor antigens |
MX2020008795A (es) * | 2018-02-28 | 2020-10-08 | Yuhan Corp | Anti cuerpos anti tigit y usos de los mismos. |
JP2021518104A (ja) * | 2018-03-14 | 2021-08-02 | デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド | 操作された細胞、t細胞免疫調節抗体、およびそれらの使用方法 |
JP7360401B2 (ja) | 2018-05-31 | 2023-10-12 | グリコネックス インコーポレイテッド | バイアンテナ型ルイスbおよびルイスy抗原に結合する治療抗体 |
WO2020018964A1 (en) | 2018-07-20 | 2020-01-23 | Fred Hutchinson Cancer Research Center | Compositions and methods for controlled expression of antigen-specific receptors |
MX2021001938A (es) | 2018-08-22 | 2021-04-19 | Fred Hutchinson Cancer Center | Inmunoterapia dirigida a antigenos kras o her2. |
CN112638944A (zh) | 2018-08-23 | 2021-04-09 | 西进公司 | 抗tigit抗体 |
CN110511912B (zh) * | 2018-08-30 | 2024-03-22 | 浙江煦顼技术有限公司 | 免疫细胞的功能调节 |
US20240165232A1 (en) | 2018-09-24 | 2024-05-23 | Fred Hutchinson Cancer Research Center | Chimeric receptor proteins and uses thereof |
CA3119188A1 (en) | 2018-11-09 | 2020-05-14 | Fred Hutchinson Cancer Research Center | T cell receptors specific for mesothelin and their use in immunotherapy |
CA3121004A1 (en) | 2018-12-19 | 2020-06-25 | Humabs Biomed Sa | Antibodies that neutralize hepatitis b virus and uses thereof |
US20220112283A1 (en) * | 2019-01-13 | 2022-04-14 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Antibodies specific to human nectin-2 |
WO2020172332A1 (en) | 2019-02-20 | 2020-08-27 | Fred Hutchinson Cancer Research Center | Binding proteins specific for ras neoantigens and uses thereof |
CA3132845A1 (en) | 2019-03-11 | 2020-09-17 | Fred Hutchinson Cancer Research Center | High avidity wt1 t cell receptors and uses thereof |
US20220242955A1 (en) * | 2019-07-11 | 2022-08-04 | Dana-Farber Cancer Institute, Inc. | Targeting galectin-9 as a therapeutic strategy for t-cell exhaustion in t-cell acute lymphoblastic leukemia |
WO2021034976A1 (en) | 2019-08-20 | 2021-02-25 | Fred Hutchinson Cancer Research Center | T-cell immunotherapy specific for wt-1 |
BR112022003698A2 (pt) | 2019-08-29 | 2022-05-24 | Vir Biotechnology Inc | Método de tratamento de uma infecção pelo vírus da hepatite b e composição farmacêutica |
EP3789485A1 (en) * | 2019-09-06 | 2021-03-10 | ONK Therapeutics Limited | Cellular therapies for cancer |
WO2021113831A1 (en) | 2019-12-05 | 2021-06-10 | Compugen Ltd. | Anti-pvrig and anti-tigit antibodies for enhanced nk-cell based tumor killing |
IL298946A (en) | 2020-06-18 | 2023-02-01 | Genentech Inc | Treatment with anti-TIGIT antibodies and PD-1 spindle-binding antagonists |
KR20230042023A (ko) | 2020-06-24 | 2023-03-27 | 비르 바이오테크놀로지, 인코포레이티드 | 조작된 b형 간염 바이러스 중화 항체 및 이의 용도 |
TW202216778A (zh) | 2020-07-15 | 2022-05-01 | 美商安進公司 | Tigit及cd112r阻斷 |
CN114163532A (zh) * | 2020-09-10 | 2022-03-11 | 南京北恒生物科技有限公司 | 包含新型共刺激结构域的嵌合抗原受体及其用途 |
WO2022066965A2 (en) | 2020-09-24 | 2022-03-31 | Fred Hutchinson Cancer Research Center | Immunotherapy targeting sox2 antigens |
WO2022066973A1 (en) | 2020-09-24 | 2022-03-31 | Fred Hutchinson Cancer Research Center | Immunotherapy targeting pbk or oip5 antigens |
TW202222841A (zh) | 2020-10-06 | 2022-06-16 | 福瑞德哈金森腫瘤研究中心 | 用於治療表現mage-a1之疾病的組成物及方法 |
CN112480264B (zh) * | 2020-11-27 | 2022-04-29 | 山东兴瑞生物科技有限公司 | 一种以tigit和pd-1为靶点的嵌合抗原受体、car-t细胞及其制备方法 |
WO2022132836A2 (en) | 2020-12-14 | 2022-06-23 | Fred Hutchinson Cancer Research Center | Compositions and methods for cellular immunotherapy |
WO2022145879A1 (ko) * | 2020-12-28 | 2022-07-07 | 연세대학교 산학협력단 | 면역 관문 저해제의 스크리닝 방법 |
WO2022164805A1 (en) | 2021-01-26 | 2022-08-04 | Vir Biotechnology, Inc. | Compositions and methods for treating hepatitis b virus infection |
AR125753A1 (es) | 2021-05-04 | 2023-08-09 | Agenus Inc | Anticuerpos anti-tigit, anticuerpos anti-cd96 y métodos de uso de estos |
WO2023288281A2 (en) | 2021-07-15 | 2023-01-19 | Fred Hutchinson Cancer Center | Chimeric polypeptides |
WO2023010094A2 (en) | 2021-07-28 | 2023-02-02 | Genentech, Inc. | Methods and compositions for treating cancer |
TW202321308A (zh) | 2021-09-30 | 2023-06-01 | 美商建南德克公司 | 使用抗tigit抗體、抗cd38抗體及pd—1軸結合拮抗劑治療血液癌症的方法 |
WO2023161943A1 (en) | 2022-02-28 | 2023-08-31 | Nectin Therapeutics Ltd. | Humanized antibodies against nectin-2 and drug conjugates thereof |
WO2023178192A1 (en) | 2022-03-15 | 2023-09-21 | Compugen Ltd. | Il-18bp antagonist antibodies and their use in monotherapy and combination therapy in the treatment of cancer |
WO2023215725A1 (en) | 2022-05-02 | 2023-11-09 | Fred Hutchinson Cancer Center | Compositions and methods for cellular immunotherapy |
WO2023230439A1 (en) | 2022-05-23 | 2023-11-30 | Vir Biotechnology, Inc. | Fc-engineered hepatitis b virus neutralizing antibodies and uses thereof |
WO2023240058A2 (en) | 2022-06-07 | 2023-12-14 | Genentech, Inc. | Prognostic and therapeutic methods for cancer |
Family Cites Families (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US4263428A (en) | 1978-03-24 | 1981-04-21 | The Regents Of The University Of California | Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same |
IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
US4475196A (en) | 1981-03-06 | 1984-10-02 | Zor Clair G | Instrument for locating faults in aircraft passenger reading light and attendant call control system |
US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
DE3374837D1 (en) | 1982-02-17 | 1988-01-21 | Ciba Geigy Ag | Lipids in the aqueous phase |
US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
US4486194A (en) | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
EP0143949B1 (en) | 1983-11-01 | 1988-10-12 | TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION | Pharmaceutical composition containing urokinase |
US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
US4751180A (en) | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・2・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
WO1988009344A1 (en) | 1987-05-21 | 1988-12-01 | Creative Biomolecules, Inc. | Targeted multifunctional proteins |
US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
KR100508289B1 (ko) | 1998-04-21 | 2005-08-17 | 마이크로메트 에이지 | Cd19×cd3 특이 폴리펩티드 및 그의 용도 |
DE69911793T2 (de) | 1998-07-28 | 2004-08-12 | Micromet Ag | Heterominikörper |
EP1481993A1 (en) * | 2003-05-28 | 2004-12-01 | Xerion Pharmaceuticals AG | Modulation of the poliovirus receptor function |
DK1673398T3 (da) | 2003-10-16 | 2011-04-18 | Micromet Ag | Multispecifikke, deimmuniserede CD3-bindere |
WO2005107799A1 (ja) * | 2004-05-06 | 2005-11-17 | Eisai R & D Management Co., Ltd. | 抗Necl-5抗体を有効成分として含む癌治療剤 |
AU2006301492B2 (en) | 2005-10-11 | 2011-06-09 | Amgen Research (Munich) Gmbh | Compositions comprising cross-species-specific antibodies and uses thereof |
PE20081456A1 (es) | 2006-10-06 | 2008-11-27 | Takeda Pharmaceutical | Anticuerpo monoclonal contra nectina 2 |
WO2008119567A2 (en) | 2007-04-03 | 2008-10-09 | Micromet Ag | Cross-species-specific cd3-epsilon binding domain |
US20110059106A1 (en) * | 2008-01-29 | 2011-03-10 | Brigham And Women's Hospital, Inc. | Methods for modulating a population of myeloid-derived suppressor cells and uses thereof |
KR101855381B1 (ko) | 2008-04-09 | 2018-05-09 | 제넨테크, 인크. | 면역 관련 질병의 치료를 위한 신규한 조성물 및 방법 |
US10981998B2 (en) | 2008-10-01 | 2021-04-20 | Amgen Research (Munich) Gmbh | Cross-species-specific single domain bispecific single chain antibody |
JP2013532153A (ja) * | 2010-06-18 | 2013-08-15 | ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド | 慢性免疫病に対する免疫治療のためのtim−3およびpd−1に対する二重特異性抗体 |
US20140234320A1 (en) * | 2011-06-20 | 2014-08-21 | La Jolla Institute For Allergy And Immunology | Modulators of 4-1bb and immune responses |
US20130078250A1 (en) | 2011-08-23 | 2013-03-28 | Oliver Ast | Bispecific t cell activating antigen binding molecules |
LT2748201T (lt) | 2011-08-23 | 2018-02-26 | Roche Glycart Ag | Dvigubai specifinė t ląsteles aktyvinantį antigeną surišanti molekulė |
KR20150090919A (ko) * | 2012-12-04 | 2015-08-06 | 온코메드 파마슈티칼스, 인크. | 결합제를 사용한 면역요법 |
AU2014236769B2 (en) | 2013-03-15 | 2018-09-27 | Amgen Inc. | Heterodimeric bispecific antibodies |
US20140308285A1 (en) | 2013-03-15 | 2014-10-16 | Amgen Inc. | Heterodimeric bispecific antibodies |
US20140302037A1 (en) | 2013-03-15 | 2014-10-09 | Amgen Inc. | BISPECIFIC-Fc MOLECULES |
EP3021869B1 (en) * | 2013-07-16 | 2020-07-15 | F. Hoffmann-La Roche AG | Methods of treating cancer using pd-1 axis binding antagonists and tigit inhibitors |
AR097648A1 (es) | 2013-09-13 | 2016-04-06 | Amgen Inc | Combinación de factores epigenéticos y compuestos biespecíficos que tienen como diana cd33 y cd3 en el tratamiento de leucemia mieloide |
EP3049440B1 (en) | 2013-09-25 | 2020-03-25 | Amgen Inc. | V-c-fc-v-c antibody |
EP3049442A4 (en) * | 2013-09-26 | 2017-06-28 | Costim Pharmaceuticals Inc. | Methods for treating hematologic cancers |
JOP20200096A1 (ar) * | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
US9300829B2 (en) | 2014-04-04 | 2016-03-29 | Canon Kabushiki Kaisha | Image reading apparatus and correction method thereof |
-
2016
- 2016-08-04 JO JOP/2016/0171A patent/JO3620B1/ar active
- 2016-08-05 LT LTEP16757165.2T patent/LT3331915T/lt unknown
- 2016-08-05 WO PCT/EP2016/068726 patent/WO2017021526A1/en active Application Filing
- 2016-08-05 TW TW105125042A patent/TWI719041B/zh active
- 2016-08-05 AU AU2016301961A patent/AU2016301961B2/en active Active
- 2016-08-05 SG SG10202000914VA patent/SG10202000914VA/en unknown
- 2016-08-05 DK DK16757165.2T patent/DK3331915T3/da active
- 2016-08-05 JP JP2018505586A patent/JP7170532B2/ja active Active
- 2016-08-05 MY MYPI2018700209A patent/MY186582A/en unknown
- 2016-08-05 CN CN201680045742.3A patent/CN108473572B/zh active Active
- 2016-08-05 SI SI201631170T patent/SI3331915T1/sl unknown
- 2016-08-05 ES ES16757165T patent/ES2861436T3/es active Active
- 2016-08-05 US US15/229,438 patent/US20170037133A1/en not_active Abandoned
- 2016-08-05 UA UAA201802157A patent/UA125375C2/uk unknown
- 2016-08-05 HU HUE16757165A patent/HUE053763T2/hu unknown
- 2016-08-05 MX MX2018001351A patent/MX2018001351A/es unknown
- 2016-08-05 EA EA201890428A patent/EA039307B1/ru unknown
- 2016-08-05 EP EP16757165.2A patent/EP3331915B1/en active Active
- 2016-08-05 CA CA2996015A patent/CA2996015A1/en active Pending
-
2017
- 2017-12-18 ZA ZA2017/08598A patent/ZA201708598B/en unknown
-
2018
- 2018-01-11 IL IL256874A patent/IL256874B/en unknown
- 2018-01-15 PH PH12018500120A patent/PH12018500120A1/en unknown
- 2018-06-22 HK HK18107990.5A patent/HK1249524A1/zh unknown
- 2018-08-31 US US16/118,994 patent/US20190077869A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EA201890428A1 (ru) | 2018-07-31 |
AU2016301961B2 (en) | 2021-10-07 |
TW201718002A (zh) | 2017-06-01 |
ZA201708598B (en) | 2021-04-28 |
LT3331915T (lt) | 2021-06-10 |
HUE053763T2 (hu) | 2021-12-28 |
CN108473572B (zh) | 2021-10-15 |
JP2018531215A (ja) | 2018-10-25 |
JO3620B1 (ar) | 2020-08-27 |
US20190077869A1 (en) | 2019-03-14 |
SI3331915T1 (sl) | 2021-08-31 |
US20170037133A1 (en) | 2017-02-09 |
SG10202000914VA (en) | 2020-03-30 |
HK1249524A1 (zh) | 2018-11-02 |
IL256874B (en) | 2022-05-01 |
IL256874A (en) | 2018-03-29 |
TWI719041B (zh) | 2021-02-21 |
EA039307B1 (ru) | 2022-01-12 |
EP3331915A1 (en) | 2018-06-13 |
EP3331915B1 (en) | 2021-02-17 |
DK3331915T3 (da) | 2021-05-03 |
CN108473572A (zh) | 2018-08-31 |
WO2017021526A1 (en) | 2017-02-09 |
AU2016301961A1 (en) | 2018-01-18 |
PH12018500120A1 (en) | 2018-07-23 |
MY186582A (en) | 2021-07-28 |
ES2861436T3 (es) | 2021-10-06 |
CA2996015A1 (en) | 2017-02-09 |
UA125375C2 (uk) | 2022-03-02 |
JP7170532B2 (ja) | 2022-11-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12018500120A1 (en) | Immune-checkpoint inhibitors for use in the treatment of blood-borne cancers | |
PH12018501952A1 (en) | Substituted inhibitors of menin-mill and methods of use | |
PH12021500004A1 (en) | Pd-1/pd-l1 inhibitors | |
PH12020550622A1 (en) | Kras g12c inhibitors | |
CY1121831T1 (el) | Παραγωγα θειενο [2,3-c] πυρρολ-4-ονης ως αναστολεις της erk | |
PH12021550152A1 (en) | Anti-cd112r compositions and methods | |
PH12018501955A1 (en) | Bridged bicyclic inhibitors of menin-mll and methods of use | |
MX2017013613A (es) | Neoepitodos de cancer. | |
WO2016062722A8 (en) | Combination | |
MX2018010473A (es) | Terapia de combinacion con anticuerpos anti cumulo de diferenciacion 73 (cd73). | |
PH12020500075A1 (en) | Checkpoint inhibitor bispecific antibodies | |
CL2018001226A1 (es) | Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer | |
MX2016006726A (es) | Composiciones que comprenden anticuerpos anti-molecula de adhesion celular relacionada con antigeno carcinoembrionario 1 y anti-muerte celular programada para la terapia contra el cancer. | |
MX2017012113A (es) | Combinacion de inhibidor de histona desacetilasa y anticuerpo anti-muerte celular programada-1 para el tratamiento de cancer. | |
MX2021007773A (es) | Compuestos inhibidores de egfr. | |
MX2017010595A (es) | Métodos, composiciones, y equipos para tratamiento de cáncer. | |
MX2018016057A (es) | Composiciones y metodos para tratar enfermedades cardiovasculares. | |
MX2018000267A (es) | Combinacion de inhibidores de histona desacetilasa y anticuerpo de ligando 1 de anti-muerte celular programada para el tratamiento de cancer. | |
WO2018081531A3 (en) | Methods for human t-cell activation | |
MX2018008008A (es) | Combinacion del inhibidor hdac y anticuerpo-pd-l1 para el tratamiento de cancer ovarico. | |
UA117983C2 (uk) | Інгібітор кінази aurora a | |
NZ738876A (en) | Motile sperm domain containing protein 2 and inflammation | |
IL276668A (en) | Thioredoxin reductase inhibitors for use in the treatment of cancer | |
GEP20196962B (en) | Pharmaceutical composition for the treatment of mycosis | |
MX2020006673A (es) | Metodos de tratamiento del cancer mediante el uso de un inhibidor de ataxia-telangiectasia mutada y rad3 (atr). |